<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7048954\results\search\drugs\results.xml">
  <result pre="first drugs used in combination with conventional pegylated interferon and" exact="ribavirin" post="therapies and significantly improved treatment outcomes.5–7 Second generation protease"/>
  <result pre="156 are &quot;hot spots�? for linear antivirals, such as first-generation" exact="telaprevir" post="and boceprevir. Additionally, mutations at position 156 also arise"/>
  <result pre="156 also arise after treatment with next-generation anti-proteases such as" exact="simeprevir" post="and grazoprevir.35 Enzyme constructs containing these mutations were tested"/>
  <result pre="J Med. 2011;364(13):1195–1206. doi:10.1056/NEJMoa101049421449783 7.ShermanKE, FlammSL, AfdhalNH, et al. Response-guided" exact="telaprevir" post="combination treatment for hepatitis C virus infection. N Engl"/>
  <result pre="treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without" exact="ribavirin" post="for hepatitis C virus genotype 1 infection in previously"/>
  <result pre="treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without" exact="ribavirin" post="in patients with hepatitis C virus genotype 1 mono-infection"/>
 </snippets>
</snippetsTree>
